Alector, Inc.
Close on Oct 19, 2026
- Market cap
- $216.89M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $3.30M | $-0.21 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $1.00M | $-0.21 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $6.20M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $3.30M | $-0.34 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $7.90M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $3.70M | $-0.41 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $54.20M | $-0.02 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $15.30M | $-0.43 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Nov 6, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total research and development expenses | 2025 | $130.00M to $140.00M | Raised |
| total general and administrative expenses | 2025 | $55.00M to $65.00M | Lowered |
| collaboration revenue | 2025 | $13.00M to $18.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Alector filed with the SEC
Alector Announces Pricing of Underwritten Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Alector Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alector Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alector Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alector Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alector Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Alector Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports First Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alector Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Alector Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K